MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis And/or Cholangiocarcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Oct 3

PMID 26431155

Citations 52

Authors

Torsten Voigtlander

Shashi K Gupta

Sabrina Thum

Jasmin Fendrich

Michael P Manns

Tim O Lankisch

Thomas Thum

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Patients with primary sclerosing cholangitis (PSC) are at high risk for the development of cholangiocarcinoma (CC). Analysis of micro ribonucleic acid (MiRNA) patterns is an evolving research field in biliary pathophysiology with potential value in diagnosis and therapy. Our aim was to evaluate miRNA patterns in serum and bile of patients with PSC and/or CC.

Methods: Serum and bile from consecutive patients with PSC (n = 40 (serum), n = 52 (bile)), CC (n = 31 (serum), n = 19 (bile)) and patients with CC complicating PSC (PSC/CC) (n = 12 (bile)) were analyzed in a cross-sectional study between 2009 and 2012. As additional control serum samples from healthy individuals were analyzed (n = 12). The miRNA levels in serum and bile were determined with global miRNA profiling and subsequent miRNA-specific polymerase chain reaction-mediated validation.

Results: Serum analysis revealed significant differences for miR-1281 (p = 0.001), miR-126 (p = 0.001), miR-26a (p = 0.001), miR-30b (p = 0.001) and miR-122 (p = 0.034) between patients with PSC and patients with CC. All validated miRNAs were significantly lower in healthy individuals. MiR-412 (p = 0.001), miR-640 (p = 0.001), miR-1537 (p = 0.003) and miR-3189 (p = 0.001) were significantly different between patients with PSC and PSC/CC in bile.

Conclusions: Patients with PSC and/or CC have distinct miRNA profiles in serum and bile. Furthermore, miRNA concentrations are different in bile of patients with CC on top of PSC indicating the potential diagnostic value of these miRNAs.

Citing Articles

RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma.

Ala U, Fagoonee S Front Mol Biosci. 2024; 11:1388294.

PMID: 38903178 PMC: 11187294. DOI: 10.3389/fmolb.2024.1388294.

Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications.

Lee S, Song S Cancers (Basel). 2024; 16(9).

PMID: 38730713 PMC: 11083053. DOI: 10.3390/cancers16091761.

Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.

Catanzaro E, Gringeri E, Burra P, Gambato M Cancers (Basel). 2023; 15(20).

PMID: 37894314 PMC: 10604939. DOI: 10.3390/cancers15204947.

Diagnostic utility of quantitative analysis of microRNA in bile samples obtained during endoscopic retrograde cholangiopancreatography for malignant biliary strictures.

Kuniyoshi N, Imazu H, Masuzaki R, Yamazaki M, Hamana S, Nomura S PLoS One. 2023; 18(8):e0289537.

PMID: 37561751 PMC: 10414614. DOI: 10.1371/journal.pone.0289537.

Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.

Hochberg J, Sohal A, Handa P, Maliken B, Kim T, Wang K JHEP Rep. 2023; 5(6):100729.

PMID: 37179785 PMC: 10172698. DOI: 10.1016/j.jhepr.2023.100729.

References

Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R . miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology. 2010; 52(6):2148-57. PMC: 3076553. DOI: 10.1002/hep.23915. View

Lankisch T, Metzger J, Negm A, Vosskuhl K, Schiffer E, Siwy J . Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011; 53(3):875-84. DOI: 10.1002/hep.24103. View

Weismuller T, Lankisch T . Medical and endoscopic therapy of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011; 25(6):741-52. DOI: 10.1016/j.bpg.2011.10.003. View

Farid W, Verhoeven C, De Jonge J, Metselaar H, Kazemier G, van der Laan L . The ins and outs of microRNAs as biomarkers in liver disease and transplantation. Transpl Int. 2014; 27(12):1222-32. DOI: 10.1111/tri.12379. View

Zhang J, Zhao C, Zhang S, Yu D, Chen Y, Liu Q . Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. Oncol Rep. 2014; 31(3):1157-64. DOI: 10.3892/or.2013.2960. View

Roest H, Verhoeven C, van der Laan L . MicroRNAs in bile vesicles: finding a trade-off for biomarker discovery. Hepatology. 2014; 61(3):1094-5. DOI: 10.1002/hep.27325. View

Nakao K, Miyaaki H, Ichikawa T . Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 2014; 49(4):589-93. DOI: 10.1007/s00535-014-0932-4. View

Bessho K, Shanmukhappa K, Sheridan R, Shivakumar P, Mourya R, Walters S . Integrative genomics identifies candidate microRNAs for pathogenesis of experimental biliary atresia. BMC Syst Biol. 2013; 7:104. PMC: 3819657. DOI: 10.1186/1752-0509-7-104. View

Yang H, Li T, Peng J, Tang X, Ko K, Xia M . A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011; 141(1):378-88, 388.e1-4. PMC: 3129489. DOI: 10.1053/j.gastro.2011.03.044. View

10.

Munoz-Garrido P, Garcia-Fernandez de Barrena M, Hijona E, Carracedo M, Marin J, Bujanda L . MicroRNAs in biliary diseases. World J Gastroenterol. 2012; 18(43):6189-96. PMC: 3501766. DOI: 10.3748/wjg.v18.i43.6189. View

11.

Williamson K, Chapman R . Primary sclerosing cholangitis. Dig Dis. 2014; 32(4):438-45. DOI: 10.1159/000358150. View

12.

Song Y, Zhao F, Wang Z, Liu Z, Chiang Y, Xu Y . Inverse association between miR-194 expression and tumor invasion in gastric cancer. Ann Surg Oncol. 2011; 19 Suppl 3:S509-17. DOI: 10.1245/s10434-011-1999-2. View

13.

Crawford M, Brawner E, Batte K, Yu L, Hunter M, Otterson G . MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008; 373(4):607-12. DOI: 10.1016/j.bbrc.2008.06.090. View

14.

Eaton J, Talwalkar J, Lazaridis K, Gores G, Lindor K . Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013; 145(3):521-36. PMC: 3815445. DOI: 10.1053/j.gastro.2013.06.052. View

15.

Skipworth J, Keane M, Pereira S . Update on the management of cholangiocarcinoma. Dig Dis. 2014; 32(5):570-8. PMC: 4158615. DOI: 10.1159/000360507. View

16.

Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, Kawahigashi Y . Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One. 2011; 6(8):e23584. PMC: 3157401. DOI: 10.1371/journal.pone.0023584. View

17.

Metzger J, Negm A, Plentz R, Weismuller T, Wedemeyer J, Karlsen T . Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2012; 62(1):122-30. DOI: 10.1136/gutjnl-2012-302047. View

18.

Visone R, Rassenti L, Veronese A, Taccioli C, Costinean S, Aguda B . Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009; 114(18):3872-9. PMC: 2773482. DOI: 10.1182/blood-2009-06-229211. View

19.

Salvucci O, Jiang K, Gasperini P, Maric D, Zhu J, Sakakibara S . MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1. Haematologica. 2012; 97(6):818-26. PMC: 3366645. DOI: 10.3324/haematol.2011.056945. View

20.

Karlsen T, Boberg K . Update on primary sclerosing cholangitis. J Hepatol. 2013; 59(3):571-82. DOI: 10.1016/j.jhep.2013.03.015. View